COMBINE 4 compares treatment with IcoSema or IGla‐100 for 40 weeks (followed by 5 weeks of follow‐up) of 474 people with T2DM naïve to insulin and GLP‐1RA. The gene discussed is INS; the disease is type 2 diabetes mellitus.